Methodological advances in laboratory hematology have led to a new type of patient: the "previvor.” These are patients with abnormal laboratory tests of unclear significance. Such results give patients a label but do not classify them as having a disease which requires specific therapy. Data on risk of progression to overt disease is emerging, but many patients live in a state of risk, neither progressing nor being assured of normal hematologic function long-term. Recently, great efforts have been undertaken to better clarify these entities, the risk of progression to clinically significant disease, optimal follow-up, and finally, if there is a subset of patients who may benefit from specific therapy. The speakers will emphasis what we know, what is hypothesized for the future, and the ethical and practical issues of caring for patients with two of these entities: CCUS and MBL. Dr. Xie will review the definitions and prevalence of clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). She will discuss strategies to estimate risk for progression, outline clinical management, and review current clinical trial opportunities. Dr. Ghia will discuss the different entities the comprise monoclonal B cell lymphocytosis (MBL) and how they may precede the development of chronic lymphocytic leukemia (CLL). He will describe how biological and clinical features can help distinguish those at risk of clinical consequences and review strategies to manage affected individuals.